(Q40409351)

20 September 2017

title

Rituximab and other emerging monoclonal antibody therapies for lymphoma (English)

1 reference

20 September 2017

1 reference

Kensei Tobinai

1

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Expert Opinion on Emerging Drugs

20 September 2017

published in

1 reference

20 September 2017

volume

7

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

289-302

1 reference

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

The emerging role of radioimmunotherapy in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.7.2.289

21 January 2018

Identifiers

DOI

10.1517/14728214.7.2.289

1 reference

20 September 2017

1 reference